: Johnson & Johnson aims to raise $3 billion in Kenvue IPO


Johnson & Johnson JNJ expects to raise roughly $3 billion in an initial public offering of its consumer-health unit. In a filing with the Securities and Exchange Commission made public Monday afternoon, Johnson & Johnson said it expects to sell more than 151 million shares in the IPO at a price of $20 to $23, which would raise roughly $3.25 billion at the midpoint price of $21.50. The parent company would retain more than 1.7 billion shares, with the total share count disclosed Monday suggesting an initial enterprise value of $40.1 billion at the midpoint of the range. The Kenvue unit includes brands such as Tylenol,…

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleEarnings Outlook: For Microsoft, AI is the future, but the present is cloudy
Next articleCoinbase asks court to force SEC to respond to its crypto-regulation petition


Please enter your comment!
Please enter your name here